Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
News May 14, 2013
Cobra Biologics will apply its cost-effective platform process to deliver a programme of host strain generation, GMP cell banking, plasmid DNA production and clinical trials supply.
Vaccibody’s technology exploits the interplay between tissue, antigen presenting cells (APC), T-cells and B-cells to develop targeted vaccines designed to induce stronger and longer lasting immune responses than traditional vaccines. The platform technology allows for the tailored development of not only enhanced prophylactic vaccines but also therapeutic vaccines against chronic infections and cancers.
Peter Coleman CEO of Cobra Biologics said “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 14 years and I am delighted that we are able to announce the partnership with Vaccibody. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development that we have successfully used for over 30 customers”.
Ole Henrik Brekke, CEO of Vaccibody said “With the significantly effective preclinical results VB 10.16 has shown, we are delighted now to take the next step towards clinical trials with Cobra Biologics as our manufacturing partner.”
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018